Does ENCORAFENIB Cause Interstitial lung disease? 48 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 48 reports of Interstitial lung disease have been filed in association with ENCORAFENIB (BRAFTOVI). This represents 0.6% of all adverse event reports for ENCORAFENIB.
48
Reports of Interstitial lung disease with ENCORAFENIB
0.6%
of all ENCORAFENIB reports
14
Deaths
24
Hospitalizations
How Dangerous Is Interstitial lung disease From ENCORAFENIB?
Of the 48 reports, 14 (29.2%) resulted in death, 24 (50.0%) required hospitalization, and 4 (8.3%) were considered life-threatening.
Is Interstitial lung disease Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for ENCORAFENIB. However, 48 reports have been filed with the FAERS database.
What Other Side Effects Does ENCORAFENIB Cause?
Death (1,004)
Off label use (989)
Nausea (758)
Fatigue (685)
Diarrhoea (574)
Neoplasm progression (548)
Pyrexia (539)
Product use in unapproved indication (506)
Vomiting (429)
Rash (414)
What Other Drugs Cause Interstitial lung disease?
METHOTREXATE (3,049)
RITUXIMAB (2,458)
PEMBROLIZUMAB (2,113)
PREDNISONE (1,850)
CYCLOPHOSPHAMIDE (1,725)
NIVOLUMAB (1,538)
AMIODARONE (1,421)
DOXORUBICIN (1,352)
ETANERCEPT (1,267)
ADALIMUMAB (1,250)
Which ENCORAFENIB Alternatives Have Lower Interstitial lung disease Risk?
ENCORAFENIB vs ENDOXAN
ENCORAFENIB vs ENDOXAN BAXTER
ENCORAFENIB vs ENDOXAN INJ
ENCORAFENIB vs ENDOXAN , POUDRE POUR
ENCORAFENIB vs ENFORTUMAB VEDOTIN